These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24732671)

  • 1. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.
    Kulkarni J; Gavrilidis E; Wang W; Worsley R; Fitzgerald PB; Gurvich C; Van Rheenen T; Berk M; Burger H
    Mol Psychiatry; 2015 Jun; 20(6):695-702. PubMed ID: 24732671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in depression with oestrogen treatment in women with schizophrenia.
    Lascurain MB; Camuñas-Palacín A; Thomas N; Breadon C; Gavrilidis E; Hudaib AR; Gurvich C; Kulkarni J
    Arch Womens Ment Health; 2020 Apr; 23(2):149-154. PubMed ID: 30903287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
    Weiser M; Levi L; Zamora D; Biegon A; SanGiovanni JP; Davidson M; Burshtein S; Gonen I; Radu P; Slobozean Pavalache K; Nastas I; Hemi R; Ryan T; Davis JM
    JAMA Psychiatry; 2019 Oct; 76(10):1009-1017. PubMed ID: 31365044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
    Bobo WV; Woodward ND; Sim MY; Jayathilake K; Meltzer HY
    Schizophr Res; 2011 Aug; 130(1-3):106-13. PubMed ID: 21641776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L; Meng X; Hochfeld M
    Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia.
    Kulkarni J; Riedel A; de Castella AR; Fitzgerald PB; Rolfe TJ; Taffe J; Burger H
    Arch Womens Ment Health; 2002 Nov; 5(3):99-104. PubMed ID: 12510212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.